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Objectives: This paper will compare the treatment of CA in the 
Philippine General Hoapital, Outpatient Arthritis 'Clinic before and 
after the 1995 publication of the Guidelines for Treatment of CA 
of the hips, knees and hands. 
Methods: This is a descriptive retrospective study of patients 
diagnosed to have osteoarthritis based on ACR criteria. It will 
compare management of patients seen in 1994 and 1999, using 
a data collection form. 
Results: 
Treatment 1994 1999 
n = 33 n=62 
(%) (%) 
Non-Pharmacological 
Education 10 (30) 50 (81) 
Weight loss 4(t2) 11 (18) 
OT 1 (3) 4(6) 
PT 17 (52) 3 (52) 
Pharmacological 
Paracetamol 11 (33) 32 (52) 
Tramadol 1 (3) 6 (10) 
Meperidine 0 0 
Codeine 0 0 
NSAIDs 30(91) 46(74) 
Topical 6(18) 2(3) 
IA Steroids 0 9(15) 
Glucosamine 0 35(56) 
HMP 33 0 7(11) 
Other Drugs 0 0 
Surgical 
Osteotomy 0 1 (2) 
Joint Replacement 0 0 
Others 0 0 
*OT occupational therapy 
*PT physical therapy 
*IA = intraarticular 
Conclusion: This is a preliminary data and so far, the trend has 
shown increasing use of the analgesics and non-pharmacologic 
treatment of osteoarthritis after issuance of the treatment guide- 
lines. NSAIDs still is the most common drug intervention used. 
Our low utilization of health support systems and psychological 
support may stem for the extended family set-up that most 
Filipinos have. 
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Aim: The aim of this study was to investigate antiarthritic effect of 
tincture from Filipendula ulmaria (L.) Maxim (FU) by using an 
experimental model of osteoarthritis (CA) in rats. 
Methods: CA was reproduced by combination of both biochem- 
ical and surgical methods. One day before the transection of 
anterior cruciate ligaments 60 rats received a single intra-articu- 
lar injection of 20 ;LI 2% dextran sulphate solution. The animals 
with CA were distributed into controls and treated groups; 10 ani- 
mals served as non-operated control. FU tincture was produced 
from wild plants growing in Lithuania (A.Keturkiene t al. Apply for 
patent N 2001 036). Three different doses of FU (4, 8 and 17 
mg/kg -1 calculated to dry weight of tincture) were given daily as 
intragastnc injections. 3 control CA groups received: acetylsali- 
cylicum acid (ASA) at a dose of 21 mg/kg -1 for salicylic com- 
pounds, ethanol 8 mg/kg -1 -- for tincture solvent, and water. The 
treatment was started one week postoperatively and lasted for 
20 days. Pathomorphological changes in joints, liver and 
stomach tissue were investigated histologically at the end of the 
experiment. 
Results: There was greatly diminished loss of acid glycosamino- 
glycans under the treatment of CA with FU tincture in doses of 8 
mg/kg -1 and 17 mg/kg -1 compared with untreated CA. A sig- 
nificant decrease of usures, fissures, thinning of cartilage and 
total cartilage degradation was also observed. The dose of FU 17 
mg/kg -1 increased synovium fibrosis. Inflammatory infiltration of 
synovium diminished 2.4 and 4.6 times under the treatment with 
FU in doses 8 mg/kg -1 and 17 mg/kg -1 respectively. Neither the 
treatment of CA with ASA nor ethanol did result in such marked 
diminishing of inflammatory infiltration. The investigation of path- 
omorphological changes in liver and stomach showed consider- 
able effect of this agent in all treated groups. 
Conclusions: This experimental model of CA in rats may be con- 
sidered as appropriate model for studying the development of 
CA and for evaluation of the anti-inflammatory and cartilage- 
preserving activities of new agents. 
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Objective: The aim of the study was to compare the fficacy of 
rofecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2), vs. 
diclofenac in patients with primary osteoarthritis (CA) of the knee. 
Methods: A series of 63 patients of both sexes (average 64, 
range 45 to 82 years), with painful knee osteoarthritis (according 
to ACR criteria and verified by radiographic evidence) were 
enrolled in a 6-week parallel, double-blind study. Following an 
initial screening visit, patients were randomized to receive, after a 
7-day NSAID-free washout period, either rofecoxib 12.5 mg or 
diclofenac sodium 100 mg once dally. Patients were assessed at 
weeks 2, 4 and 6, and the results were measured by the WOMAC 
osteoarthritis index (version 3.0) with use of visual analog scale 
(VAS). 
Results: Thirty-four ofecoxib and twenty-nine diclofenactreated 
patients participated in the trial. Statistically significant (p<0.01) 
improvements in all three dimensions of the WOMAC osteoarthri- 
tis index were noted in both treatment groups as compared to the 
baseline results. At the doses studied, no differences between the 
drugs in stiffness variables were observed. However, statistically 
significant differences favoring rofecoxib (p£0.05) in most of pain 
and physical function criteria were observed. Additionally, no sig- 
nificant difference between the two drugs was noted in tolerabil- 
ity. There were no serious adverse effects of the drugs during the 
trial. 
Conclusion= Specific inhibition of COX-2 by rofecoxib 12.5 mg, 
administered once daily, resulted in a clinical improvement in 
patients with CA. Rofecoxib is efficacious and well tolerated in 
patients with CA of the knee. In this group of patients it was sim- 
ilar in tolerability and superior in efficacy to diclofenac 100 
mg/day. Thus the benefit/risk ratio of rofecoxib was superior to 
that of dictofenac in this study. 
